Skip to main content

Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients

Abstract

Background

Rabbit antithymocyte globulins (rATGs) are polyclonal antibodies used to prevent acute cellular rejection in kidney transplantation. Their dosing remains largely empirical and the question of an individualized dose is still unresolved.

Methods

Data from a prospective study in 17 kidney transplant patients were used to develop a model describing the dose–concentration–response relationship of rATG with T-lymphocyte subpopulation counts over time. The model was validated using an independent cohort of kidney transplant patients treated by rATG in the same center.

Results

Pharmacokinetics of rATG was described using a two-compartment model integrating a third compartment and a target-mediated elimination for active rATG. The kinetics of CD3+, CD4+, CD8+, and CD3CD56+ cell counts over time were described by a pharmacokinetic-pharmacodynamic model with transit compartments, integrating both CD3CD56+-independent and CD3CD56+-dependent rATG-mediated lymphocyte depletion, and a positive feedback. Elimination of rATG was influenced by age and body surface area, while its distribution was also influenced by body surface area. CD3+ proliferation rate decreased with age and CD3CD56+-mediated elimination was influenced by the V158F-FCGR3A polymorphism. Binary efficacy and tolerance endpoints were defined as a CD3+ count < 20 mm–3 for at least 7 days and a CD4+ count > 200 mm–3 at 1 year, respectively. Simulations showed that increasing or decreasing the standard 6-mg/kg dose will impact both tolerance and efficacy, while a dose decrease may be beneficial in elderly patients.

Conclusions

Our results can be used to design prospective clinical trials testing dose individualization based on patients’ characteristics.

Clinical Trial Registration

Eudract No. 2009-012673-35.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs. 2010;70:691–732.

    Article  CAS  Google Scholar 

  2. 2.

    Mourad G, Morelon E, Noël C, Glotz D, Lebranchu Y. The role of thymoglobulin induction in kidney transplantation: an update. Clin Transplant. 2012;26:E450–64.

    Article  CAS  Google Scholar 

  3. 3.

    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–8.

    Article  CAS  Google Scholar 

  4. 4.

    Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664–9.

    Article  Google Scholar 

  5. 5.

    Koene HR, Kleijer M, Algra J, Roos D. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgammaRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood. 1997;90:1109–14.

    Article  CAS  Google Scholar 

  6. 6.

    Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, Fujimoto K, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19:629–35.

    Article  CAS  Google Scholar 

  7. 7.

    Ducloux D, Bamoulid J, Daguindau E, Rebibou JM, Courivaud C, Saas P. Antithymocytes globulins: time to revisit its use in kidney transplantation? Int Rev Immunol. 2018;37:183–91.

    Article  CAS  Google Scholar 

  8. 8.

    Kho MML, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26:186–90.

    Article  CAS  Google Scholar 

  9. 9.

    Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transpl Immunol. 2013;28:120–6.

    Article  CAS  Google Scholar 

  10. 10.

    Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, et al. Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. Pharmacogenet Genomics. 2014;24:26–34.

    Article  CAS  Google Scholar 

  11. 11.

    Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9:460–71.

    Article  CAS  Google Scholar 

  12. 12.

    Gatault P, Lajoie L, Stojanova J, Halimi J, Caillard S, Moyrand S, et al. The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients: a retrospective study. Transpl Int. 2020;33:936–47.

    Article  CAS  Google Scholar 

  13. 13.

    Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.

    Article  CAS  Google Scholar 

  14. 14.

    Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713–21.

    Article  Google Scholar 

  15. 15.

    Zandvliet AS, Schellens JHM, Dittrich C, Wanders J, Beijnen JH, Huitema ADR. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol. 2008;66:485–97.

    Article  CAS  Google Scholar 

  16. 16.

    Segura C, Bandrés E, Trocóniz IF, García-Foncillas J, Sayar O, Dios-Vieítez C, et al. Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res. 2004;21:567–73.

    Article  CAS  Google Scholar 

  17. 17.

    Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.

    Article  Google Scholar 

  18. 18.

    Büchler M, Thibault G, Al Najjar A, Valentin J-F, Guerraoui A, Nivet H, et al. Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation. Transplant Proc. 1996;28:2817–8.

    PubMed  Google Scholar 

  19. 19.

    Ata P, Kara M, Özdemir E, Canbakan M, Gökçe AM, Bayraktar FA, et al. Monitoring of CD3+ T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation. Transplant Proc. 2013;45:929–31.

    Article  CAS  Google Scholar 

  20. 20.

    Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, et al. Immune reconstitution following rabbit antithymocyte globulin: immune reconstitution. Am J Transplant. 2010;10:2132–41.

    Article  CAS  Google Scholar 

  21. 21.

    Lavielle M. mlxR: simulation of longitudinal data. 2019. https://CRAN.R-project.org/package=mlxR. Accessed 28 Jun 2021.

  22. 22.

    Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996;45:29–32.

    PubMed  CAS  Google Scholar 

  23. 23.

    Guttmann RD, Caudrelier P, Alberici G. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc. 1997;29:24S-26S.

    Article  CAS  Google Scholar 

  24. 24.

    Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R, US Thymoglobulin Multi-Center Study Group. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol. 2001;9:29–36.

    Article  CAS  Google Scholar 

  25. 25.

    Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, et al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin®) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15:274–8.

    Article  CAS  Google Scholar 

  26. 26.

    Admiraal R, van Kesteren C, Jon-van der Zijde CM, van Tol MJD, Bartelink IH, Bredius RGM, et al. Population pharmacokinetic modeling of Thymoglobulin® in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. 2015;54:435–46.

    Article  CAS  Google Scholar 

  27. 27.

    Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, et al. A fully automated method for the determination of serum belatacept and its application in a pharmacokinetic investigation in renal transplant recipients. Ther Drug Monit. 2019;41:11–8.

    Article  CAS  Google Scholar 

  28. 28.

    Li H, Han TH, Hunder NN, Jang G, Zhao B. Population pharmacokinetics of brentuximab vedotin in patients with CD30-expressing hematologic malignancies. J Clin Pharmacol. 2017;57:1148–58.

    Article  CAS  Google Scholar 

  29. 29.

    Zierhut ML, Gastonguay MR, Martin SW, Vicini P, Bekker PJ, Holloway D, et al. Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women. J Pharmacokinet Pharmacodyn. 2008;35:379–99.

    Article  CAS  Google Scholar 

  30. 30.

    Diao L, Li S, Ludden T, Gobburu J, Nestorov I, Jiang H. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet. 2014;53:467–77.

    Article  CAS  Google Scholar 

  31. 31.

    Bouazza N, Urien S, Neven B, Moshous D, Nisoy J, Gabrion A, et al. Evaluation of antithymocyte globulin pharmacokinetics and pharmacodynamics in children. J Allergy Clin Immunol. 2016;137:306-9.e4.

    Article  CAS  Google Scholar 

  32. 32.

    Djamali A, Turc-Baron C, Portales P, Leverson G, Chong G, Clot J, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation. 2000;69:799–805.

    Article  CAS  Google Scholar 

  33. 33.

    Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin®) in solid organ transplants, stem cell transplants and autoimmunity. Drugs. 2014;74:1605–34.

    Article  CAS  Google Scholar 

  34. 34.

    Nafar M, Dalili N, Poor-Reza-Gholi F, Ahmadpoor P, Samadian F, Samavat S. The appropriate dose of thymoglobulin induction therapy in kidney transplantation. Clin Transplant. 2017;31:e12977.

    Article  CAS  Google Scholar 

  35. 35.

    Pankewycz O, Leca N, Kohli R, Wallace PK, Said M, Feng L, et al. Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc. 2011;43:462–5.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Djamila Lemay and Crystal Sung from Genzyme for the rATG concentration measurements.

Author information

Affiliations

Authors

Corresponding author

Correspondence to David Ternant.

Ethics declarations

Funding

The study was sponsored by Tours University Hospital and benefited from a grant from Genzyme (Sanofi). This work was partly supported by the French Higher Education and Research Ministry under the program ‘Investissements d’avenir’ Grant Agreement: LabEx MAbImprove ANR-10-LABX-53-01.

Conflicts of Interest/Competing Interests

Nicolas Azzopardi, Hélène Longuet, Gilles Thibault, Valérie Gouilleux-Gruart, Yvon Lebranchu, Matthias Büchler, and Philippe Gatault have no conflicts of interest that are directly relevant to the content of this article. David Ternant has given lectures for Amgen, Sanofi, Novartis, and Boehringer-Inghelheim, outside of the submitted work. Gilles Paintaud reports research grants from Amgen, Chugai, Lilly, Merck, Novartis, Shire (Takeda,) and Roche Pharma, outside of the submitted work.

Ethics approval

The protocol was approved by the local ethics committee.

Consent to participate

Written informed consent was obtained from all patients.

Consent for publication

Not applicable.

Code availability

The code is available on request to the corresponding author.

Availability of data and material

Data and material are available on request to the corresponding author.

Authors’ contributions

NA analyzed the data, performed the research and wrote the manuscript. HL included patients and collected and analyzed the data. DT analyzed the data and reviewed the research. GT produced and interpreted data and reviewed the research. VGG produced and interpreted the data. YL designed the research and included patients. MB included patients and reviewed the research. PG analyzed the data, designed and reviewed the research, and wrote the manuscript. GP designed the research, analyzed the data, reviewed the research, and wrote the manuscript. All authors reviewed the final version of the manuscript.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 2522 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Azzopardi, N., Longuet, H., Ternant, D. et al. Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. Clin Pharmacokinet (2021). https://doi.org/10.1007/s40262-021-01053-7

Download citation